Exogenous insulin does not reduce protein catabolism in pre-diabetic cystic fibrosis patients: A randomized clinical trial
Recent advances in CF have led to remarkable clinical improvements. In this study, CF youth with AGT had normal protein catabolism at baseline. Pre-meal or daily basal insulin therapy, while safe and well tolerated, did not significantly enhance protein turnover and does not appear to be necessary in clinically stable patients prior to development of CFRD.
Authors
- K. Sreekumaran Nair (ORCID: https://orcid.org/0000-0002-0649-9469)
- Antoinette Moran (ORCID: https://orcid.org/0000-0002-2694-5147)
- Gianna Toffolo
- Claudio Cobelli (ORCID: https://orcid.org/0000-0002-0169-6682)
- Katherine A. Klaus
- Michele Schiavon (ORCID: https://orcid.org/0000-0003-0590-2399)
- Lin Zhang (ORCID: https://orcid.org/0000-0002-0003-6084)
Institutions
- University of Minnesota (US)
- Mayo Clinic (US)
- University of Padua (IT)
- Mayo Clinic in Arizona (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- Journal of Cystic Fibrosis
- Published
- 2024-11-08
- DOI
- https://doi.org/10.1016/j.jcf.2024.10.005
- Citations
- 4
- Primary Topic
- Cystic Fibrosis Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 1.68
Funders
- Mayo Clinic
- Cystic Fibrosis Foundation
- Leona M. and Harry B. Helmsley Charitable Trust
- University of Minnesota
- Novo Nordisk
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Center for Advancing Translational Sciences